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Abstract
Background: Armed conflicts are increasingly impacting countries with a high burden of 
cancer. The aim of this study is to systematically review the literature on the impact of 
armed conflict on cancer in low- and middle-income countries (LMICs). 
Methods: In November 2019, we searched five medical databases (Embase, Medline, 
Global Health, PsychINFO and the Web of Science) without date, language or study 
design restrictions. We included studies assessing the association between armed con-
flict and any cancer among civilian populations in LMICs. We systematically re-analysed 
the data from original studies and assessed quality using the Newcastle-Ottawa Scale. 
Data were analysed descriptively by cancer site.
Results: Of 1,543 citations screened, we included 20 studies assessing 8 armed conflicts 
and 13 site-specific cancers (total study population: 70,172). Two-thirds of the studies 
were of low methodological quality (score <5) and their findings were often conflicting. 
However, among outcomes assessed by three or more studies, we found some evidence 
that armed conflict was associated with increases in the incidence and mortality of non-
specific cancers, breast cancer and cervical cancer. Single studies reported a positive 
association between armed conflict and the incidence of stomach and testicular cancers, 
some as early as 3 years after the onset of conflict. Some studies reported a post-conflict 
impact on time to diagnosis.
Conclusion: Our findings support the need for more rigorous longitudinal and cohort stud-
ies of populations in and immediately post-conflict to inform the development of basic 
packages of cancer services, and post-conflict cancer control planning and development. 
Keywords: cancer, conflict, war, systematic review, low-income countries, middle-income 
countries
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Cancer caused 8.7 million deaths globally in 2015, making it the second leading cause of death after cardiovascular disease [1]. Although this 
figure is likely to be an underestimate [2], the burden of cancer is increasing in low- and middle-income countries (LMICs), where 80% of the 
world’s population live [3] and where about two-thirds of all cancer deaths occur [4]. This is due to increasing life expectancy coupled with 
changing patterns of behavioural risk factors associated with higher non-communicable disease risk, such as tobacco and alcohol use, obesity, 
physical inactivity and an unhealthy diet [5]. Occupational, environmental and dietary exposure to carcinogens also account for substantial 
numbers of cancer deaths [2]. Calls for better cancer prevention and early diagnosis and better treatment all form part of Target 3.4 of the Sus-
tainable Development Goals (SDGs), which aims for a one-third reduction in premature mortality from non-communicable diseases by 2030 [6].
Efforts to meet SDG Target 3.4, and indeed other SDGs, are likely to be hampered by the presence of armed conflict. In 2018, there were 
52 armed conflicts where at least one party was a government of state, and a record 82 active civil wars [7]. Although the number of armed 
conflicts has been increasing, the number of deaths occurring in armed conflicts has been markedly decreasing. Armed conflicts may increase 
cancer incidence, complications and mortality in the short term by disrupting patients seeking care and the delivery of all aspects of oncologi-
cal care [9, 10]. Additional impacts on cancer services may result from sudden demographic shifts associated with armed conflict and forced 
migration (internally displaced persons or refugees). This may increase late diagnoses for potentially curable site-specific cancers, abandon-
ment of treatment or sub-optimal treatment, all of which increase the burden of cancer on patients and health services. 
Longer-term impacts of armed conflict on cancer incidence may also be a result of the toxic contamination of the environment. Examples 
include the Vietnam War, where 10% of south Vietnam was sprayed with the carcinogenic Agent Orange [11] and the Second World War 
where atomic bombs were dropped on the Japanese cities of Hiroshima and Nagasaki [12]. Furthermore, stress experienced during armed 
conflict may encourage unhealthy behaviours that increase the risk of cancer, such as tobacco and alcohol use [16–18]. Finally, mass popu-
lation displacement increases the risk of communicable disease transmission, which can increase the infectious causes of cancer, such as 
human papillomavirus and chlamydia trachomatis (cervical cancer), Epstein–Barr virus (nasopharyngeal cancer and lymphomas), hepatitis B 
and C (liver cancer, non-Hodgkin lymphoma) and others.
The greater number and increasingly protracted nature of conflict globally warrants a better understanding of its relationship to cancer care 
and cancer mortality. Understanding the relationship between armed conflict and cancer is important as more conflicts occur in demographi-
cally and epidemiologically transitioned societies. It remains unclear which short- or long-term approaches are most important in mediating 
the impact of armed conflict on cancer burden, and whether any of these factors are feasibly modifiable during an active conflict or in the 
post-conflict setting. This study aimed to review the literature for the impact of armed conflict on cancer, in particular its incidence and 
mortality among civilians in LMICs.
Methods
This systematic review is registered on Prospero (ID: CRD42017065722) and follows the PRISMA reporting standards [20]. Our research 
questions is: ‘What is the association between armed conflict and cancer for civilians in LMICs, compared to civilians with less or no exposure 
to armed conflict?’
";-u1_v|u-|;]-m7v;Ѳ;1ࢼom1ub|;ub-
We searched five electronic databases (Embase, Medline, Global Health, PsychINFO and the Web of Science) in November 2019 without 
language or date restrictions, using synonyms for armed conflict, cancer and LMICs. The full search strategy can be found in Table S1. We 
also hand-searched citation lists of included studies to identify additionally relevant articles. In line with previous reviews, we did not search 
the grey literature given the limited information available [21].
The inclusion criteria comprised civilian populations (including children, internally displaced persons, and refugees) in LMICs exposed to 
author-defined armed conflict with a diagnosis of any type of cancer. We did not exclude studies by design but a component of comparison 
to a non- or less-conflict exposed group was required for eligibility. In the case of ecological studies collecting serial data points over time 
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(e.g., hospital admission data pre-, during- and post-conflict), we excluded studies whose first post-conflict data point was greater than 3 
years after the end of the conflict. 
We excluded studies reporting on military veterans, combatants and studies from high-income countries (including where refugees had 
migrated to high-income countries). We also excluded studies whose exposure was weapons (often, nuclear) testing rather than armed con-
flict. Studies that mentioned armed conflict but did not attempt to measure it were further excluded. 
Data analysis
Two reviewers performed all citation screening and data abstraction in duplicate and independently using pilot-tested forms. Disagreements 
were resolved by discussion, and when needed with the help of a third reviewer. We retrieved full texts of citations considered eligible by at 
least one reviewer. Data extracted from eligible studies included study provenance (funding source, ethics approval and conflicts of interest), 
study features (design, timing, conflict, country and level of jurisdiction), population (sample size, mean age/age range and percentage of 
males) and results (outcome measure definition, outcome measure effect size and precision). We calculated the maximum number of years 
from the onset or end of conflict to the time of data collection, to give an indication of the length of armed conflict exposure. We used the 
Newcastle-Ottawa Scale (NOS) [22–24] to assess the quality of each study. The NOS has been recommended for use for non-randomised 
studies by the Cochrane Collaboration [25]. Although the NOS has no established threshold of quality, in line with previous reviews [26, 27], 
we defined studies as low quality (score <5), moderate quality (score 5–6) and high quality (score >6) to simplify the main analysis. Quality 
scores by NOS domains (selection, comparability and outcome) for each study are detailed in Table S2.
Meta-analysis was not feasible given the degree of between-study heterogeneity in design, armed conflict, population and outcome. We, 
therefore, analysed data descriptively. To standardise our analytical approach and to reduce bias, we systematically re-analysed reported data 
and presented a single effect estimate per outcome per study where possible. This included constructing 95% confidence intervals around 
all effect estimates and considering confidence intervals that did not overlap as statistically significant at an alpha level of 0.05. This also 
meant we combined outcomes stratified by population subgroups (e.g., by age and sex), and used the overall outcome in our analysis. We 
did not reanalyse data already presented as odds ratios, beta-coefficients or hazard ratios. Where data were available pre- during- and post-
conflict, we used a single estimate for the differences between the pre- versus during-conflict data for each study. Furthermore, an analysis 
of post-conflict data was undertaken separately to understand better changes in trends throughout the conflict cycle. Each outcome from 
each study was assigned a qualitative effect direction (increase, decrease or no change) following exposure to armed conflict based on the 
statistical significance of effects. We stratified our analysis by cancer incidence and mortality, and outcomes with greater than three studies 
were described in more detail and displayed graphically using Harvest plots. Harvest plots take aspects of a forest plot to display data on a 
matrix of effect direction weighted by several variables [28]. Finally, we visually assessed publication bias by constructing an adapted funnel 
plot, using the sample size and the qualitative effect direction in place of the standard error and effect size, respectively.
Results
"|71_-u-1|;ubvࢼ1v
Of 1,543 records identified through database searching, 38 were potentially eligible and 20 were included in the final analysis (Figure 1). The 
total study population was 70,172. Three-quarters of studies used an ecological design (75.0%) and over one-third analysed the Croatian War 
of Independence (1991–1995) (35.0%). Over half were conducted in cities (55.0%) and 70.0% utilised hospital-derived data. The average 
follow-up time was 16.8 years (range 3–64 years) and study quality was mostly rated as low (65.0%). Only four outcomes were assessed by 
three or more studies: the incidence of any, breast and cervical cancer, and mortality from any cancer.
Incidence of any cancer
Four studies, all low quality and ecological, assessed the incidence of any type of cancer (Figure 2, top left panel). One subnational cancer 
registry study analysed non-specific conflicts in Iraq over 30 years and showed an increase in the incidence rate ratio of cancers throughout 
the conflict and into the post-conflict period [29]. It did not compare incidence rate ratios in similar countries not at war during this period 
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of time. Two hospital-based studies from the Balkans showed no change in cancer incidence during the conflict compared to the pre-conflict 
baseline [30, 31]. Another cancer registry study assessed the Lebanese Civil War and showed no change in cancer incidence during the con-
flict period (1983–1991, mean 786 cases/year) compared to the post-conflict period (1992 to 1994, mean 802.3 cases/year) [32].
Mortality from any cancer
Four studies assessed mortality from any cancer (Figure 2, bottom left panel). One moderate-to-high quality study assessed the 2003 US-led 
invasion of Iraq and reported an average 50% increase in the number of households reporting cancer deaths from the pre-conflict period 
(mean 9.9 cases/year in 2001–2002) to the conflict period (mean 14.8 cases/year in 2003–2010) [33]. We calculated this difference to be 
statistically significant (4.9 cases/year, 95% CI 0.4–9.4). Two survivor cohort studies from the Siege of Leningrad (1941–1944) reported no 
change in cancer mortality 41 to 64 years after the siege although both adjusted hazard ratios showed positive effect estimates (1.12 (95% 
CI 0.95 -1.31) and 1.11 (95% CI 0.97 -1.27)) [34, 35]. One modelling study (1973 to 1994) used data from the Federal Institute of Statistics 
to assess the impact of the breakup of Yugoslavia, and found that cancer mortality decreased during periods of war and sanctions [36].
Breast cancer incidence
Six studies, all assessing wars in the Balkans during the 1990s, reported on breast cancer incidence (Figure 2, top right panel). Both moderate-
to-high quality studies showed an increase in breast cancer incidence [37, 38]. One of these was ecological in design, monitored trends 13 years 
before the 1999 NATO bombing of Yugoslavia, and reported an increase from an average of 67.2 cases/year before the conflict to 80.2 cases/
year during the conflict [38]. We calculated this difference to be statistically significant (13.0 cases/year, 95% CI 4.1–21.9). The other study used 
a case-control design and reported increased odds of breast cancer among those with greater exposure to war-related events in Bosnia (pooled 
odds across all events: 1.55, 95% CI 1.37–1.73) [37]. The remaining four studies, all low quality and ecological in design, showed no change [39, 
40] or a decrease [31, 41] in breast cancer incidence. The study with the shortest follow-up in this review (3 years) was one study that showed 
a decrease in breast cancer diagnosis during the Croatian War of Independence (32 cases in 2 years) compared to the pre-conflict baseline (86 
cases in 2 years) [31]ĺ);1omvb7;u;7|_bv7;1u;-v;v|-|bv|b1-ѴѴvb]mb=b1-m|ŐƴƔƓĺƏ1-v;vņƑ;-uvķƖƔѷŋƕƔĺƒ|oƴƒƑĺƕőĺ
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Cervical cancer incidence
Three studies assessed cervical cancer incidence (Figure 2, bottom right panel). One moderate-to-high quality case-control study of the 
Vietnam War showed that women with a husband in the army had higher odds of cervical cancer compared to those without (adjusted odds 
ratio (AOR) 1.32, 95% CI: 1.00–1.75) [42]. One low-quality ecological study in Greece assessed over 35,000 smear tests from hospitals with 
different proximity to the Yugoslav border, but showed no difference in either cervical cancer or cervical intraepithelial neoplasia incidence 
between the sites following the NATO bombing of Yugoslavia in 1999 [43]. Another low-quality hospital-based ecological study found a 
decrease in cervical cancer incidence, from 214 cases in 6 years before the Croatian war, to 142 in 6 years of the war [44]. We found this to 
0;-v|-|bv|b1-ѴѴvb]mb=b1-m|7;1u;-v;ŐƴƕƑĺƏķƖƔѷĹƴƐƏƖĺƏ|oƴƒƔĺƏőĺ
b]u;Ƒĺ$_;blr-1|o=-ul;71omYb1|om1-m1;ubm1b7;m1;-m7lou|-Ѵb|ĺm|;uru;|-ঞomĹ;b]_|u;=;uv|ov|7t-Ѵb|ķ1oѴouu;=;uv|o-ul;71omYb1|ķ
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Characteristic % (N)
Year of publication 1999 or earlier 5.0 (1)
2000–2009 70.0 (14)
2010 or later 25.0  (5)
Funding source Reported 25.0 (5)
None declared 10.0 (2)
Not reported 65.0 (13)
Ethics approval Yes 25.0 (5)
No 10.0 (2)
Not reported 65.0 (13)
Study design Ecological 75.0 (15)
Case-control 10.0 (2)
Cohort 10.0 (2)
Cross-sectional 5.0 (1)
Armed conflict Croatian War of Independence (1991–1995) 35.0 (7)
Bosnian War (1992–1995) 15.0 (3)
Siege of Leningrad (1941–1944) 10.0 (2)
NATO bombing of Yugoslavia (1999) 10.0 (2)
Iraq War (2003–2011) 5.0 (1)
Unspecified conflicts in Iraq 5.0 (1)
Lebanese Civil War (1975–1991) 5.0 (1)
Sri Lankan Civil War (1983–2009) 5.0 (1)
Vietnam War (1955–1975) 5.0 (1)
Unspecified conflicts following the breakup of Yugoslavia 5.0 (1)
Level of jurisdiction City 55.0 (11)
Subnational 25.0 (5)
National 20.0 (4)
Setting Hospital 70.0 (14)
Community 30.0 (6)
ul;71om=Ѵb1|;rovu;l;-vu;l;m| Uniform exposure to all based on time and place 80.0 (16)
Exposure based on time of birth 10.0 (2)
Exposure to specific armed conflict events 5.0 (1)
Exposure based having a relative in the military 5.0 (1)
Time between conflict and outcome Less than 5 years 15.0 (3)
5.0–9.9 years 25.0 (5)
10.0–39.9 years 50.0 (10)
40 years or more 10.0 (2)
Newcastle-Ottawa Scale Low quality (score <5) 65.0 (13)
Moderate quality (score 5–6) 25.0 (5)
High quality (score >6) 10.0 (2)
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Other cancers
Eight studies examined other site-specific cancers, but they were too few to display graphically and describe collectively. One hospital-based 
study from Croatia reported a rise in the incidence of malignant stomach and testicular cancers when comparing 2 years of conflict to 2 years 
prior [31]. Other studies of various study design and quality found no association between armed conflict and mortality from breast cancer 
[34, 35], colon cancer [34], lung cancer [34, 35] and stomach cancer [34], nor the incidence of corpus cancer [44], haematological cancers 
[45], lung cancer [31], pancreatic cancer [31] and prostate cancer [34]. One study reported a decrease in the incidence of colon cancer [31]. 
Finally, four studies reported mixed evidence for changes in the incidence of intracranial [46, 47], oropharyngeal [48] and ovarian [31, 44] 
cancers.
ov|ň1omYb1||u;m7v
All seven studies that assessed the conflict cycle (i.e., pre-conflict, conflict and post-conflict) were ecological, hospital-based studies analys-
ing either the Croatian or Bosnian wars of the 1990s [30, 39, 41, 44–47]. The three studies that reported no change between the times 
before and during the conflict then showed an increase in incidence in the post-conflict period [30, 39, 44]. The one study that reported an 
increase in incidence between the pre- and during-conflict periods found that this increase was sustained into the post-conflict period [47]). 
In the three studies that reported a decrease in incidence between the pre- and during-conflict periods found that this either plateaued [41, 
46] or returned to pre-conflict levels [44] during the post-conflict period. One ecological study showed mixed findings in the incidence of 
haematological cancers depending on the type of conflict exposure used (areas affected by depleted uranium, chemical damage or popula-
tion mixing) and outcome (Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, lymphatic leukaemia and myeloid leukaemia), but generally found 
either no change or a decrease in incidence through the post-conflict period [45].
0Ѳb1-ࢼom0b-v
Figure 3 presents an adapted funnel plot to assess publication bias, which includes all 55 outcomes from the 20 included studies. While the 
absence of actual effect estimates limits interpretation, the plot does not present convincing evidence of asymmetry or the absence of small 
studies showing no effect, which are indicative of publication bias.
b]u;ƒĺ7-r|;7=mm;ѴrѴo|-vv;vvbm]r0Ѵb1-ঞom0b-vĺ
Re
vi
ew
ecancer 2020, 14:1039; www.ecancer.org; DOI: https://doi.org/10.3332/ecancer.2020.1039 8
Discussion
The literature on the impact of armed conflict on cancer incidence and mortality is very sparse, methodologically poor, and often contradic-
tory. This is despite the fact that some have extensive follow-up periods, which averaged 18 years. The main limitations to many studies were 
their design, namely, ecological, and thus subject to ecological fallacies; nearly all failed to acknowledge this, in addition to failing to account 
for sudden population demographic changes following forced migration. There was also limited adjustment for confounding variables in risk 
factor exposure and behaviour changes. The lack of data on factors, which may mediate the impact of armed conflict on cancer, is an addi-
tional serious limitation in the extant literature. 
The one cancer (breast) that did have several studies showing an increase in incidence following armed conflict did not have, however, suf-
ficient data to advance understanding of plausible aetiological factors. Armed conflict has been shown to change reproductive strategies 
in populations affected with greater parity and lower maternal age, both of which are protective of breast cancer [49]. Thus it is unclear, 
whether the increased incidence of breast cancer is real or an artefact.
The factors that affect cancer incidence and mortality in armed conflict are multifactorial and multilevel; these includes changes to risk factor 
exposure, behavioural changes, delays to presentation, the availability of timely and affordable complex care (depending on the site-specific 
cancer), the ability to access care, etc. Furthermore, the ability to collect reliable data from registries, hospitals or camps can be substantially 
hampered during periods of conflict. In some cases, this is because systems are destroyed, data are not collected (too costly or to protect 
patients identities) or because care data are fragmented across multiple disconnected places of care [50, 51]. Reported data may be inaccu-
rate due to limited diagnostic facilities and available pathologists, so any statistical inference should provide a contextual interrogation to the 
quality of the data. Reduced case ascertainment featured prominently as a serious lacunae in data collected during the Lebanese Civil War 
(1975–1991), when the American University of Beirut Medical Center (AUBMC) was the only functioning cancer referral site in the entire 
county and it was estimated at least two-thirds of the cancer burden during this period went either undiagnosed or unreported [32]. AUBMC 
and other cancer centres only become accessible after the end of the conflict [32], so any increase in incidence during the post-conflict 
period may simply reflect a return of the status quo. A similar conclusion was reached in analysing the cancer incidence data collected during 
the Croatian War of Independence; road blockades across the country and the removal of free care services such as breast cancer check-
ups radically reduced health service accessibility [40]. In another analysis of the same conflict, an observed post-conflict increase in cancer 
incidence was also attributed to the introduction of a new cancer screening programme, better organisation of cancer care services and the 
introduction of more accurate and up-to-date diagnostic equipment in hospitals [39]. 
In armed conflict, there is an expected rise in cancer-related mortality due to the loss of skilled personnel, the shift of such personnel into 
acute care, shortage or failure of key equipment—diagnostic imaging, surgical instruments, radiotherapy and cancer drugs, for example—and 
the inability of patients to access what care remains due to security or affordability barriers, all factors that led to the rise in cancer mortality 
during the armed conflict in Serbia in 1999 [38]. Yet it is possible that the same factors that worsen cancer mortality are the same that inhibit 
the timely and accurate reporting of such mortality, which may explain why many of the studies included in this review reported no change 
in the incidence or mortality of cancer during or after armed conflict. 
Better quality research to study cancer in armed conflict is essential, and our review findings have several research implications. Although 
resources are often scarce in conflict settings, making use of hospital-based registries or other sources of routinely collected data have 
excellent potential for robust inquiry. In instances where control groups are not feasible, data could be subject to interrupted time series 
or difference-in-difference analyses with adjustment for confounders or with age-/sex-standardised rates of cancer incidence. Importantly, 
researchers should outline the status of screening programmes and other mediators in the relationship between armed conflict and cancer, 
so that these can be appropriately accounted for in the study design. This will make a more informative contribution to the current literature 
which is lacking in methodological rigour and often reports crude numbers over time. One notable absence from the literature was studies 
from humanitarian organisations. Although often unable to collect pre-conflict data, they are in a strong position to assess the degree of 
conflict exposure among their patients using tools such as the Harvard Trauma Questionnaire [52]. Future research could assess the impact 
of armed conflict on stage of diagnosis, in addition to inequalities by socioeconomic groups (e.g. age, sex, residence and deprivation). Most 
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studies with very long follow-up times (>30 years) hypothesised that in utero, infant or adolescent exposure to armed conflict would have a 
greater impact on cancer risk to those exposed at older ages [34, 35, 53]. However, the failure to properly control for the many confounders 
has seriously hampered research to examine the link between toxic contamination of the environment due to armed conflict and long-term 
health impacts such as cancer. 
Our findings also have important policy implications. Despite a number of guidance documents on cancer care in complex emergencies and 
post disaster, e.g., post typhoon Haiyan issued by WHO [54, 55] the literature is silent on what might constitute basic packages of cancer 
care, for UN and international NGOs for example and on approaches to post-conflict cancer systems reconstruction, or in supporting host 
countries absorb and provide care to refugees in both formal and informal (sans papier) settings. Although, it is to be recognised that the lat-
ter is intimately linked to post-conflict health systems reconstruction per se. More research is needed to urgently inform cancer policies and 
planning in the context of armed conflicts, particularly now that so many are occurring in high-burden countries with populations that have 
gone through the demographic and epidemiological transitions.
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1 exp Neoplasms/ 7676601 Advanced
2 cancer*.tw. 3996712 Advanced
3 neoplas*.tw. 776165 Advanced
4 tumo*.tw. 3765025 Advanced
5 carcinoma*.tw. 1485187 Advanced
6 hodgkin*.tw. 157060 Advanced
7 nonhodgkin*.tw. 526 Advanced
8 adenocarcinoma*.tw. 332994 Advanced
9 leukemia*.tw. 499875 Advanced
10 leukaemia*.tw. 104081 Advanced
11 metastat*.tw. 515966 Advanced
12 sarcoma*.tw. 303922 Advanced
13 teratoma*.tw. 34024 Advanced
14 malignan*.tw. 1308813 Advanced
15 lymphoma*.tw. 407427 Advanced
16 melanoma*.tw. 258240 Advanced
17 myeloma*.tw. 127994 Advanced
18 oncolog*.tw. 364356 Advanced
19 Armed Conflict/ 31610 Advanced
20 exp Warfare/ 54929 Advanced
21 exp War Exposure/ 546 Advanced
22 ((armed or zone) adj2 conflict*).tw. 3756 Advanced
23 war.tw. 115433 Advanced
24 wars.tw. 11819 Advanced
25 (“conflict affected” adj3 (population* or person* or communit*)).mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq, 
bt, id, cc, nm, kf, px, rx, ui, sy, tc, tm]
280 Advanced
26 wartime.tw. 5286 Advanced
27 warfare.tw. 13281 Advanced
28 or/19–27 187756 Advanced
29 Developing Countries.sh,kf. 86834 Advanced
30 ((developing or less* developed or under developed or underdeveloped or middle income or low* income or 
underserved or under served or deprived or poor*) adj (countr* or nation? or population? or world)).ti,ab.
254072 Advanced
31 (low* adj (gdp or gnp or gross domestic or gross national)).ti,ab. 635 Advanced
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32 (low adj3 middle adj3 countr*).ti,ab. 31781 Advanced
33 (lmic or lmics or third world or lami countr*).ti,ab. 16495 Advanced
34 transitional countr*.ti,ab. 497 Advanced
35 Cambodia/ 9676 Advanced
36 (cambodia* or Kampuchea).cp,in,jw,mp. 16070 Advanced
37 “Democratic People’s Republic of Korea”/ 948 Advanced
38 (north korea* or (democratic people* republic adj2 korea)).cp,in,jw,mp. 2909 Advanced
39 Myanmar/ 7472 Advanced
40 (myanmar or burma or burmese).cp,in,jw,mp. 14657 Advanced
41 Fiji/ 2699 Advanced
42 fiji*.cp,in,jw,mp. 7124 Advanced
43 Indonesia/ 31608 Advanced
44 indonesia*.cp,in,jw,mp. 70992 Advanced
45 Micronesia/ 2722 Advanced
46 (Micronesia* or Kiribati).cp,in,jw,mp. 4452 Advanced
47 Laos/ 4998 Advanced
48 (laos or (lao adj1 democratic republic) or (lao adj2 people) or marshall island*).cp,in,jw,mp. 8856 Advanced
49 Mongolia/ 5352 Advanced
50 mongolia*.cp,in,jw,mp. 33254 Advanced
51 Papua New Guinea/ 12436 Advanced
52 Papua New Guinea.cp,in,jw,mp. 18499 Advanced
53 Philippines/ 23256 Advanced
54 (Philippines or filipino*).cp,in,jw,mp. 56650 Advanced
55 samoa/ or “independent state of samoa”/ 1436 Advanced
56 samoa*.cp,in,jw,mp. 4406 Advanced
57 Melanesia/ 6561 Advanced
58 (Solomon Islands or Timor-Leste or Melanesia*).cp,in,jw,mp. 10868 Advanced
59 Tonga/ 780 Advanced
60 tonga*.cp,in,jw,mp. 2796 Advanced
61 Vanuatu/ 1076 Advanced
62 Vanuatu.cp,in,jw,mp. 1929 Advanced
63 Vietnam/ 31470 Advanced
64 Vietnam*.cp,in,jw,mp. 63695 Advanced
65 exp China/ 488990 Advanced
66 (china or chinese).cp,in,jw,mp. 4029109 Advanced
67 Malaysia/ 43933 Advanced
68 Malaysia*.cp,in,jw,mp. 161810 Advanced
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69 Palau/ 517 Advanced
70 (Palau or Belau or Pelew).cp,in,jw,mp. 2785 Advanced
71 Thailand/ 74175 Advanced
72 (Thailand or thai*).cp,in,jw,mp. 258491 Advanced
73 (tuvalu or ellice islands).cp,in,jw,mp. 252 Advanced
74 Kyrgyzstan/ 3071 Advanced
75 (kyrgyzstan or kyrgyz or kirghizia or kirghiz).cp,in,jw,mp. 5329 Advanced
76 Tajikistan/ 1997 Advanced
77 (tajikistan or tadzhik or tadzhikistan or tajikistan).cp,in,jw,mp. 3145 Advanced
78 Albania/ 3252 Advanced
79 Albania*.cp,in,jw,mp. 7781 Advanced
80 Armenia/ 3513 Advanced
81 Armenia*.cp,in,jw,mp. 15700 Advanced
82 “Georgia (Republic)”/ 3447 Advanced
83 georgia*.cp,in,jw,mp. 309463 Advanced
84 Yugoslavia/ 20384 Advanced
85 (Jugoslavija* or Yugoslavia* or serbo-croat* or macedonia* or sloven* or kosovo).cp,in,jw,mp. 182508 Advanced
86 Moldova/ 2093 Advanced
87 Moldova*.cp,in,jw,mp. 7233 Advanced
88 Ukraine/ 33163 Advanced
89 Ukrain*.cp,in,jw,mp. 177783 Advanced
90 Uzbekistan/ 4970 Advanced
91 Uzbekistan.cp,in,jw,mp. 9683 Advanced
92 Azerbaijan/ 3477 Advanced
93 Azerbaijan*.cp,in,jw,mp. 10050 Advanced
94 “Republic of Belarus”/ 4521 Advanced
95 (belarus or byelarus or belorussia).cp,in,jw,mp. 18740 Advanced
96 Bosnia-Herzegovina/ 5557 Advanced
97 bosnia*.cp,in,jw,mp. 26942 Advanced
98 Bulgaria/ 19189 Advanced
99 Bulgaria*.cp,in,jw,mp. 132182 Advanced
100 Kazakhstan/ 7280 Advanced
101 (Kazakhstan or kazakh).cp,in,jw,mp. 15369 Advanced
102 Latvia/ 4309 Advanced
103 Latvia*.cp,in,jw,mp. 14271 Advanced
104 Lithuania/ 7989 Advanced
105 Lithuania*.cp,in,jw,mp. 32645 Advanced
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106 “Macedonia (Republic)”/ 1499 Advanced
107 Macedonia*.cp,in,jw,mp. 18485 Advanced
108 Montenegro/ 1011 Advanced
109 Montenegro.cp,in,jw,mp. 12126 Advanced
110 Romania/ 29547 Advanced
111 Romania*.cp,in,jw,mp. 192775 Advanced
112 exp Russia/ 121816 Advanced
113 USSR/ 100452 Advanced
114 (russia* or ussr or soviet or cccp).cp,in,jw,mp. 1730511 Advanced
115 Serbia/ 10350 Advanced
116 serbia*.cp,in,jw,mp. 102530 Advanced
117 Turkey/ 62130 Advanced
118 turk*.cp,in,jw,mp. not animal/ 704949 Advanced
119 Turkmenistan/ 1504 Advanced
120 Haiti/ 8175 Advanced
121 Haiti/ 8175 Advanced
122 Haiti.cp,in,jw,mp. 11219 Advanced
123 Belize/ 1561 Advanced
124 Belize.cp,in,jw,mp. 2633 Advanced
125 Bolivia/ 7577 Advanced
126 Bolivia*.cp,in,jw,mp. 14352 Advanced
127 El Salvador/ 3218 Advanced
128 El Salvador.cp,in,jw,mp. 6430 Advanced
129 Guatemala/ 9325 Advanced
130 Guatemala*.cp,in,jw,mp. 16832 Advanced
131 Guyana/ 1884 Advanced
132 Guyana*.cp,in,jw,mp. 4005 Advanced
133 Honduras/ 3571 Advanced
134 Hondura*.cp,in,jw,mp. 6496 Advanced
135 Nicaragua/ 4511 Advanced
136 Nicaragua.cp,in,jw,mp. 6910 Advanced
137 Paraguay/ 2836 Advanced
138 Paraguay.cp,in,jw,mp. 9550 Advanced
139 “Antigua and Barbuda”/ 323 Advanced
140 (Antigua or Barbuda).cp,in,jw,mp. 2739 Advanced
141 Argentina/ 43847 Advanced
142 Argentin*.cp,in,jw,mp. 318227 Advanced
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143 Brazil/ 251275 Advanced
144 Brazil*.cp,in,jw,mp. 1132518 Advanced
145 Chile/ 33657 Advanced
146 Chile*.cp,in,jw,mp. 163635 Advanced
147 Colombia/ 32939 Advanced
148 Colombia*.cp,in,jw,mp. 99092 Advanced
149 Costa Rica/ 9961 Advanced
150 Costa Rica*.cp,in,jw,mp. 25767 Advanced
151 Cuba/ 36428 Advanced
152 Cuba*.cp,in,jw,mp. 56766 Advanced
153 Dominica/ 346 Advanced
154 Dominican Republic/ 4480 Advanced
155 Dominica*.cp,in,jw,mp. 12555 Advanced
156 Ecuador/ 9999 Advanced
157 Ecuador*.cp,in,jw,mp. 21748 Advanced
158 Grenada/ 497 Advanced
159 Grenad*.cp,in,jw,mp. 5679 Advanced
160 Jamaica/ 8829 Advanced
161 Jamaica*.cp,in,jw,mp. 32769 Advanced
162 Mexico/ 94503 Advanced
163 Mexic*.cp,in,jw,mp. 510292 Advanced
164 exp Panama/ 6410 Advanced
165 Peru/ 24083 Advanced
166 Peru*.cp,in,jw,mp. 121963 Advanced
167 Saint Lucia/ 370 Advanced
168 (St Lucia* or Saint Lucia*).cp,in,jw,mp. 31049 Advanced
169 “Saint Vincent and the Grenadines”/ 188 Advanced
170 Grenadines.cp,in,jw,mp. 388 Advanced
171 Suriname/ 2500 Advanced
172 Surinam*.cp,in,jw,mp. 5356 Advanced
173 Uruguay/ 6062 Advanced
174 Uruguay.cp,in,jw,mp. 33620 Advanced
175 Venezuela/ 15615 Advanced
176 Venezuela*.cp,in,jw,mp. 62459 Advanced
177 Djibouti/ 765 Advanced
178 Djibouti.cp,in,jw,mp. 1328 Advanced
179 Egypt/ 45378 Advanced
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180 Egypt*.cp,in,jw,mp. 256076 Advanced
181 Iraq/ 14342 Advanced
182 Iraq*.cp,in,jw,mp. 41190 Advanced
183 Morocco/ 16925 Advanced
184 Morocc*.cp,in,jw,mp. 53607 Advanced
185 Syria/ 4345 Advanced
186 (Syria* or gaza*).cp,in,jw,mp. 46343 Advanced
187 Yemen/ 4328 Advanced
188 yemen*.cp,in,jw,mp. 8741 Advanced
189 Algeria/ 9423 Advanced
190 Algeria*.cp,in,jw,mp. 28210 Advanced
191 Iran/ 103314 Advanced
192 Iran*.cp,in,jw,mp. 430404 Advanced
193 Jordan/ 11829 Advanced
194 jordan*.cp,in,jw,mp. 82444 Advanced
195 Lebanon/ 10587 Advanced
196 Leban*.cp,in,jw,mp. 81259 Advanced
197 Libya/ 3479 Advanced
198 Libya*.cp,in,jw,mp. 9106 Advanced
199 Tunisia/ 21063 Advanced
200 Tunisia*.cp,in,jw,mp. 75717 Advanced
201 Afghanistan/ 9699 Advanced
202 Afghan*.cp,in,jw,mp. 21898 Advanced
203 Bangladesh/ 32929 Advanced
204 Bangladesh*.cp,in,jw,mp. 67526 Advanced
205 Nepal/ 22054 Advanced
206 Nepal*.cp,in,jw,mp. 40842 Advanced
207 Bhutan/ 1384 Advanced
208 Bhutan*.cp,in,jw,mp. 4424 Advanced
209 exp India/ 328701 Advanced
210 india*.cp,in,jw,mp. 2185658 Advanced
211 Pakistan/ 51913 Advanced
212 Pakistan*.cp,in,jw,mp. 188131 Advanced
213 Sri Lanka/ 17094 Advanced
214 Sri Lanka*.cp,in,jw,mp. 34681 Advanced
215 Indian Ocean Islands/ 6825 Advanced
216 Maldiv*.cp,in,jw,mp. 1041 Advanced
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217 Benin/ 5525 Advanced
218 (Benin or Dahomey).cp,in,jw,mp. 19616 Advanced
219 Burkina Faso/ 10413 Advanced
220 (Burkina Faso or Burkina Fasso or Upper Volta).cp,in,jw,mp. 17067 Advanced
221 Burundi/ 1927 Advanced
222 Burundi*.cp,in,jw,mp. 2942 Advanced
223 Central African Republic/ 2420 Advanced
224 (Central African Republic or Ubangi-Shari or african*).cp,in,jw,mp. 680868 Advanced
225 Chad/ 2287 Advanced
226 Chad.cp,in,jw,mp. 11223 Advanced
227 Comoros/ 820 Advanced
228 (comoros or comores).cp,in,jw,mp. 1314 Advanced
229 “Democratic Republic of the Congo”/ 10599 Advanced
230 (congo* or zaire).cp,in,jw,mp. 54233 Advanced
231 Eritrea/ 1024 Advanced
232 Eritrea*.cp,in,jw,mp. 5415 Advanced
233 Ethiopia/ 33164 Advanced
234 Ethiopia*.cp,in,jw,mp. 50473 Advanced
235 Gambia/ 7090 Advanced
236 Gambia*.cp,in,jw,mp. 27765 Advanced
237 Guinea/ 6270 Advanced
238 (Guinea* not (New Guinea or Guinea Pig* or Guinea Fowl)).cp,in,jw,mp. 18108 Advanced
239 Guinea-Bissau/ 2564 Advanced
240 (Guinea-Bissau or Portuguese Guinea).cp,in,jw,mp. 3632 Advanced
241 Kenya/ 45802 Advanced
242 Kenya*.cp,in,jw,mp. 110143 Advanced
243 Liberia/ 3651 Advanced
244 Liberia*.cp,in,jw,mp. 6151 Advanced
245 Madagascar/ 9500 Advanced
246 (Madagasca* or Malagasy Republic).cp,in,jw,mp. 16045 Advanced
247 Malawi/ 15425 Advanced
248 (Malawi* or Nyasaland).cp,in,jw,mp. 24406 Advanced
249 Mali/ 7677 Advanced
250 Mali*.cp,in,jw,mp. 1529474 Advanced
251 Mauritania/ 1375 Advanced
252 Mauritania*.cp,in,jw,mp. 2215 Advanced
253 Mozambique/ 7310 Advanced
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254 (Mozambi* or Portuguese East Africa).cp,in,jw,mp. 12219 Advanced
255 Niger/ 4346 Advanced
256 (Niger not (Aspergillus or Peptococcus or Schizothorax or Cruciferae or Gobius or Lasius or Agelastes or Mela-
nosuchus or radish or Parastromateus or Orius or Apergillus or Parastromateus or Stomoxys)).cp,in,jw,mp.
11622 Advanced
257 Rwanda/ 6725 Advanced
258 (Rwanda* or Ruanda*).cp,in,jw,mp. 11039 Advanced
259 Sierra Leone/ 4600 Advanced
260 Sierra Leone*.cp,in,jw,mp. 7230 Advanced
261 Somalia/ 4197 Advanced
262 Somali*.cp,in,jw,mp. 8619 Advanced
263 Tanzania/ 32576 Advanced
264 Tanzania*.cp,in,jw,mp. 48125 Advanced
265 Togo/ 3452 Advanced
266 Togo*.cp,in,jw,mp. 8974 Advanced
267 Uganda/ 34870 Advanced
268 Uganda*.cp,in,jw,mp. 67334 Advanced
269 Zimbabwe/ 15699 Advanced
270 (Zimbabwe* or Rhodesia*).cp,in,jw,mp. 31240 Advanced
271 Cameroon/ 16397 Advanced
272 Cameroon*.cp,in,jw,mp. 31218 Advanced
273 Cape Verde/ 624 Advanced
274 Cape Verde*.cp,in,jw,mp. 1521 Advanced
275 Congo/ 6707 Advanced
276 (congo* not ((democratic republic adj3 congo) or congo red or crimean-congo)).cp,in,jw,mp. 18230 Advanced
277 Cote d’Ivoire/ 9588 Advanced
278 (Cote d’Ivoire or Ivory Coast).cp,in,jw,mp. 17382 Advanced
279 Ghana/ 23375 Advanced
280 (Ghan* or Gold Coast).cp,in,jw,mp. 80459 Advanced
281 Lesotho/ 1422 Advanced
282 (Lesotho or Basutoland).cp,in,jw,mp. 2419 Advanced
283 Nigeria/ 86757 Advanced
284 Nigeria*.cp,in,jw,mp. 183806 Advanced
285 Atlantic Islands/ 1622 Advanced
286 (sao tome adj2 principe).cp,in,jw,mp. 484 Advanced
287 Senegal/ 15789 Advanced
288 Senegal*.cp,in,jw,mp. 36157 Advanced
289 Sudan/ 15334 Advanced
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290 Sudan*.cp,in,jw,mp. 36837 Advanced
291 Swaziland/ 1918 Advanced
292 Swazi*.cp,in,jw,mp. 3736 Advanced
293 Zambia/ 13256 Advanced
294 (Zambia* or Northern Rhodesia*).cp,in,jw,mp. 21380 Advanced
295 Angola/ 3012 Advanced
296 Angola*.cp,in,jw,mp. 5174 Advanced
297 Botswana/ 5298 Advanced
298 (Botswana* or Bechuanaland or Kalahari).cp,in,jw,mp. 9991 Advanced
299 Gabon/ 4399 Advanced
300 Gabon*.cp,in,jw,mp. 8593 Advanced
301 Mauritius/ 1812 Advanced
302 (Mauriti* or Agalega Islands).cp,in,jw,mp. 6514 Advanced
303 Namibia/ 3077 Advanced
304 Namibia*.cp,in,jw,mp. 5578 Advanced
305 Seychelles/ 944 Advanced
306 Seychelles.cp,in,jw,mp. 1946 Advanced
307 South Africa/ 106477 Advanced
308 South Africa*.cp,in,jw,mp. 359112 Advanced
309 or/29–308 16250440 Advanced
310 or/1–18 9906832 Advanced
311 310 and 28 and 309 15681 Advanced
312 exp animals/ not humans.sh. 32246772 Advanced
313 311 not 312 5415 Advanced
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Table S2. Characteristics of individual studies.
Breast cancer
Author, funding, ethics Study design and setting Study characteristics Outcome
;Ѵb1-ƑƏƏƑ
• Funding: Not 
reported
• Ethics: Not 
reported
• Design: Ecological
• Conflict: Croatian War of 
Independence (1991 to 
1995)
• Jurisdiction: City
• Setting: Hospital
• Exposure: Uniform
• Study year: 1980–2000
• Sample size: 2,274
• Age: Not reported
• % Male: 0
• Time between exposure and 
outcome: 15 years
• NOS Score: 4
 – Selection: 3
 – Comparability: 0
 – Outcome: 1
• Outcome: Breast cancer
• Measured: Hospital records
• Epidemiological measure: Incidence
• Effect estimate and direction (recalculated):
 – Pre-conflict: Mean 142.2 cases/year
 – During conflict: Mean 66.4 cases/year
 – Post-conflict: Mean 75.6 cases/year
• Difference:
 – Pre- versus during conflict:
 – ƴƕƔĺѶŐƖƔѷƴƐƑѶĺƐ|oƴƑƒĺƔő
 – Decrease
 – Pre- versus post-conflict:
 – ƴѵѵĺѵŐƖƔѷƴƐƐƖĺƓ|oƴƐƒĺѶő
 – Decrease
 – During versus post-conflict:
 – ƖĺƑŐƖƔѷƴѵĺƒ|oƑƓĺƕő
 – No change
	lb|uob1ƑƏƏѵ
• Funding: Yes
• Ethics: Not 
reported
• Design: Ecological
• Conflict: Croatian War of 
Independence (1991 to 
1995)
• Jurisdiction: City
• Setting: Hospital
• Exposure: Uniform
• Study year: 1990–1993
• Sample size: 118
• Age: Not reported
• % Male: Not reported
• Time between exposure and 
outcome: 3 years
• NOS Score: 4
 – Selection: 3
 – Comparability: 0
 – Outcome: 1
• Outcome: Malignant breast cancer
• Measured: Pathohistological confirmation
• Epidemiological measure: Incidence
• Effect estimate and direction (recalculated): 
 – Pre-conflict: 86 cases in 2 years
 – During conflict: 32 cases in 2 years
 – 	b==;u;m1;ĹƴƔƓĺƏŐƖƔѷƴƕƔĺƒ|oƴƒƑĺƕő
 – Decrease
-f7b1ƑƏƏƖ
• Funding: Not 
reported
• Ethics: No
• Design: Ecological
• Conflict: Croatian War of 
Independence (1991 to 
1995)
• Jurisdiction: Subnational
• Setting: Hospital
• Exposure: Uniform
• Study year: 1986–2000
• Sample size: 514
• Age: Not reported
• % Male: 1
• Time between exposure and 
outcome: 14 years
• NOS Score: 4
 – Selection: 3
 – Comparability: 0
 – Outcome: 1
• Outcome: Breast cancer
• Measured: Histological confirmation
• Epidemiological measure: Incidence
• Effect estimate and direction (recalculated):
 – Pre-conflict: 140 cases in 5 years
 – During conflict: 156 cases in 5 years
 – Post-conflict: 223 cases in 5 years
• Difference:
 – Pre- versus during conflict:
 – ƐѵĺƏŐƖƔѷƴƐѶĺƑ|oƓƖĺƑő
 – No change
 – Pre- versus post-conflict:
 – 83.0 (95% CI 44.3 to 120.7)
 – Increase
 – During versus post-conflict:
 – 67.0 (95% CI 28.8 to 105.2)
 – Increase
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Breast cancer
Author, funding, ethics Study design and setting Study characteristics Outcome
-u;Ѵob1ƑƏƏƑ
• Funding: Not 
reported
• Ethics: Not 
reported
• Design: Ecological
• Conflict: Croatian War of 
Independence (1991 to 
1995)
• Jurisdiction: City
• Setting: Hospital
• Exposure: Uniform
• Study year: 1988–1993
• Sample size: 768
• Age: 19 to 88 years
• % Male: 2
• Time between exposure and 
outcome: 7 years
• NOS Score: 4
 – Selection: 3
 – Comparability: 0
 – Outcome: 1
• Outcome: Breast cancer
• Measured: Not reported
• Epidemiological measure: Incidence
• Effect estimate and direction (recalculated): 
 – Pre-conflict: Mean 129 cases/year
 – During conflict: Mean 127 cases/year
 – 	b==;u;m1;ĹƴƑĺƕŐƖƔѷƴƑƖĺƑ|oƑƒĺƖő
 – No change”
ou7-Ŋ(b7b1ƑƏƐƔ
• Funding: Not 
reported
• Ethics: Yes
• Design: Case control
• Conflict: Bosnian War 
(1992–1995)
• Jurisdiction: National
• Setting: Hospital
• Exposure: Exposed to 
specific armed conflict 
events
• Study year: 2008–2009
• Sample size: 200
• Age: 58 years
• % Male: 0
• Time between exposure and 
outcome: 17 years
• NOS Score: 6
 – Selection: 3
 – Comparability: 2
 – Outcome: 1
• Outcome: Breast cancer
• Measured: Hospital records
• Epidemiological measure: Odds ratio
• Effect estimate and direction (recalculated):
 – 1.55 (95% CI 1.37 to 1.73)
 – Increase
orbѴƑƏƏƖ
• Funding: Yes
• Ethics: Yes
• Design: Cohort
• Conflict: Siege of Lenin-
grad (1941–1944)
• Jurisdiction: City
• Setting: Community
• Exposure: Time of birth
• Study year: 2005
• Sample size: 4,172
• Age: 49 years
• % Male: 78
• Time between exposure and 
outcome: 64 years
• NOS Score: 7
 – Selection: 3
 – Comparability: 2
 – Outcome: 2 
• Outcome: Breast cancer mortality
• Measured: Death certificates coded by physicians  
(ICD-8)
• Epidemiological measure: Adjusted hazard ratios
• Effect estimate and direction (as reported): 
 – 2.40 (95% CI 0.86 to 6.72)
 – No change
;|uob1ƑƏƏƒ
• Funding: Not 
reported
• Ethics: Not 
reported
• Design: Ecological
• Conflict: NATO bombing 
of Yugoslavia (1999)
• Jurisdiction: City
• Setting: Hospital
• Exposure: Uniform
• Study year: 1986–1999
• Sample size: 1,206
• Age: Not reported
• % Male: 0
• Time between exposure and 
outcome: 13 years
• NOS Score: 5
 – Selection: 4
 – Comparability: 0
 – Outcome: 1”
• Outcome: Breast cancer
• Measured: Hospital records
• Epidemiological measure: Incidence
• Effect estimate and direction (recalculated): 
 – Pre-conflict: Mean 67.2/year
 – During conflict: Mean 80.2/year
 – Difference: 13.0 (95% CI 4.1 to 21.9)
 – Increase
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Breast cancer
Author, funding, ethics Study design and setting Study characteristics Outcome
(-];uoƑƏƐƒ
• Funding: Yes
• Ethics: Yes
• Design: Cohort
• Conflict: Siege of Lenin-
grad (1941–1944)
• Jurisdiction: City
• Setting: Community
• Exposure: Time of birth
• Study year: 1975–1977 (men); 
1980–1982 (women)
• Sample size: 5,327
• Age: Not reported
• % Male: 73
• Time between exposure and 
outcome: 41 years
• NOS Score: 3
 – Selection: 2
 – Comparability: 0
 – Outcome: 1
• Outcome: Breast cancer mortality
• Measured: Death certificates coded by physicians  
(ICD-8)
• Epidemiological measure: Relative risk
• Effect estimate and direction (as reported): 
 – 1.89 (95% CI 0.83 to 4.31)
 – No change
Cervical cancer
Author, funding, ethics Study design and setting Study characteristics Outcome
m_ƑƏƏƓ
• Funding: Not 
reported
• Ethics: Yes
• Design: Case control
• Conflict: Vietnam War 
(1955–1975)
• Jurisdiction: City
• Setting: Hospital
• Exposure: Husband in 
army
• Study year: 1996
• Sample size: 225
• Age: Not reported
• % Male: 0
• Time between exposure and 
outcome: 21 years
• NOS Score: 5
 – Selection: 2
 – Comparability: 2
 – Outcome: 1
• Outcome: Cervical cancer
• Measured: Biopsy confirmed
• Epidemiological measure: Odds ratio
• Effect estimate and direction (as reported): 
 – 1.32 (95% CI 1.00 to 1.75)
 – Increase
bѴofhob1ƑƏƏƔ
• Funding: Not 
reported
• Ethics: Not 
reported
• Design: Ecological
• Conflict: Croatian War of 
Independence (1991 to 
1995)
• Jurisdiction: City
• Setting: Hospital
• Exposure: Uniform
• "|7;-uĹƐƖѶƓƴƑƏƏƑ
• Sample size: 567
• Age: Not reported
• % Male: Not reported
• Time between exposure and 
outcome: 10 years
• NOS Score: 4
 – Selection: 3
 – Comparability: 0
 – Outcome: 1
• Outcome: Cervical cancer
• Measured: Histological confirmation
• Epidemiological measure: Incidence
• Effect estimate and direction (recalculated):
 – Pre-conflict: 214 cases in 6 years
 – During conflict: 142 cases in 6 years
 – Post-conflict: 211 cases in 6 years
• Difference:
 – Pre- versus during conflict:
 – ƴƕƑĺƏŐƖƔѷƴƐƏƖĺƏ|oƴƒƔĺƏő
 – Decrease
 – Pre- versus post-conflict:
 – ƴƒĺƏŐƖƔѷƴƒƖĺѶ|oƒƒĺѶő
 – No change
 – During versus post-conflict:
 – 69.0 (95% CI 32.2 to 105.8)
 – Increase
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Cervical cancer
Author, funding, ethics Study design and setting Study characteristics Outcome
-r-|_-m-vboƑƏƏƔ
• Funding: Not 
reported
• Ethics: Not 
reported
• Design: Ecological
• Conflict: NATO bombing 
of Yugoslavia (1999)
• Jurisdiction: Subnational
• Setting: Hospital
• Exposure: Uniform
• Study year: 1997–2002
• Sample size: 742
• Age: 37–40 years
• %Male: 0
• Time between exposure and 
outcome: 3 years
• NOS Score: 4
 – Selection: 3
 – Comparability: 0
 – Outcome: 1
• Outcome: Cervical cancer
• Measured: Hospital records
• Epidemiological measure: Odds ratio
• Effect estimate and direction (recalculated): 
 – Exposed: 3/5,485 smears
 – Unexposed: 9 cases/30,007 smears
 – OR: 1.82 (95% CI 0.52 to 3.13)
 – No change
-r-|_-m-vboƑƏƏƔ
• Funding: Not 
reported
• Ethics: Not 
reported
• Design: Ecological
• Conflict: NATO bombing 
of Yugoslavia (1999)
• Jurisdiction: Subnational
• Setting: Hospital
• Exposure: Uniform
• Study year: 1997–2002
• Sample size: 742
• Age: 37–40 years
• %Male: 0
• Time between exposure and 
outcome: 3 years
• NOS Score: 4
 – Selection: 3
 – Comparability: 0
 – Outcome: 1
• Outcome: CIN 1–3
• Measured: Hospital records
• Epidemiological measure: Incidence
• Effect estimate and direction (recalculated): 
 – Exposed: 61 cases/5,485 smears
 – Unexposed: 266 cases/30,007 smears
 – AOR 1.26 (95% CI 0.98 to 1.54)
 – No change
Cancers of the central nervous system
Author, funding, ethics Study design and setting Study characteristics Outcome
Ѵ-f0;]ob1ƑƏƏƑ
• Funding: Not 
reported
• Ethics: Not 
reported
• Design: Ecological
• Conflict: Bosnian War 
(1992–1995)
• Jurisdiction: City
• Setting: Hospital
• Exposure: Uniform
• Study year: 1990–1999
• Sample size: 279
• Age: 60 years
• %Male: 58
• Time between exposure and 
outcome: 7 years
• NOS Score: 4
 – Selection: 3
 – Comparability: 0
 – Outcome: 1
• Outcome: CNS Cancers
• Measured: Hospital records
• Epidemiological measure: Incidence
• Effect estimate and direction (recalculated):
 – Pre-conflict: 39.4 cases/year
 – During conflict: 18.1 cases/year
 – Post-conflict: 30.8 cases/year
• Difference:
 – Pre- versus during conflict:
 – ƴƑƐĺƒŐƖƔѷƴƒѵĺƑ|oƴѵĺƓő
 – Decrease
 – Pre- versus post-conflict:
 – ƴѶĺѵŐƖƔѷƴƑƑĺƒ|oƔĺƐő
 – No change
 – During versus post-conflict:
 – ƐƑĺƕŐƖƔѷƴƐĺƏ|oƑѵĺƓő
 – No change
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Cancers of the central nervous system
Author, funding, ethics Study design and setting Study characteristics Outcome
$;Ѵ-uob1ƑƏƏѵ
• Funding: Not 
reported
• Ethics: Not 
reported
• Design: Ecological
• Conflict: Croatian War of 
Independence (1991 to 
1995)
• Jurisdiction: Subnational
• Setting: Hospital
• Exposure: Uniform
• Study year: 1986–2000
• Sample size: 364
• Age: 57 years
• % Male: 58
• Time between exposure and 
outcome: 9 years
• NOS Score: 4
 – Selection: 3
 – Comparability: 0
 – Outcome: 1
• Outcome: Intracranial tumours
• Measured: CT, EEG, NMR, histological evaluation
• Epidemiology: Incidence
• Effect direction:
 – Pre- versus during conflict: Increase
 – Pre- versus post-conflict: Increase
 – During- versus post-conflict: No change
Colon cancer
Author, funding, ethics Study design and setting Study characteristics Outcome
	lb|uob1ƑƏƏѵ
• Funding: Yes
• Ethics: Not 
reported
• Design: Ecological
• Conflict: Croatian War of 
Independence (1991 to 
1995)
• Jurisdiction: City
• Setting: Hospital
• Exposure: Uniform
• Study year: 1990–1993
• Sample size: 98
• Age: Not reported
• % Male: Not reported
• Time between exposure and 
outcome: 3 years
• NOS Score: 4
 – Selection: 3
 – Comparability: 0
 – Outcome: 1
• Outcome: Malignant colon cancer
• Measured: Pathohistological confirmation
• Epidemiological measure: Incidence
• Effect estimate and direction (recalculated): 
 – Pre-conflict: 61 cases in 2 years
 – During conflict: 37 cases in 2 years
 – 	b==;u;m1;ĹƴƑƓĺƏŐƖƔѷƴƓƒĺƓ|oƴƓĺѵő
 – Decrease
orbѴƑƏƏƖ
• Funding: Yes
• Ethics: Yes
• Design: Cohort
• Conflict: Siege of Lenin-
grad (1941–1944)
• Jurisdiction: City
• Setting: Community
• Exposure: Time of birth
• Study year: 2005
• Sample size: 4,172
• Age: 49 years
• % Male: 78
• Time between exposure and 
outcome: 64 years
• NOS Score: 7
 – Selection: 3
 – Comparability: 2
 – Outcome: 2
• Outcome: Colorectal cancer mortality
• Measured: Death certificates coded by physicians  
(ICD-8)
• Epidemiological measure: Adjusted hazard ratios
• Effect estimate and direction (as reported): 
 – 0.81 (95% CI 0.50 to 1.33)
 – No change
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Cancer of the corpus
Author, funding, ethics Study design and setting Study characteristics Outcome
bѴofhob1ƑƏƏƔ
• Funding: Not 
reported
• Ethics: Not 
reported
• Design: Ecological
• Conflict: Croatian War of 
Independence (1991 to 
1995)
• Jurisdiction: City
• Setting: Hospital
• Exposure: Uniform
• Study year: 1984–2002
• Sample size: 451
• Age: Not reported
• % Male: Not reported
• Time between exposure and 
outcome: 10 years
• NOS Score: 4
 – Selection: 3
 – Comparability: 0
 – Outcome: 1
• Outcome: Corpus cancer, unspecified
• Measured: Histological confirmation
• Epidemiological measure: Incidence
• Effect estimate and direction (recalculated):
 – Pre-conflict: 133 cases in 6 years
 – During conflict: 126 cases in 6 years
 – Post-conflict: 192 cases in 6 years
• Difference:
 – Pre- versus during conflict:
 – ƴƕĺƏŐƖƔѷƴƒѶĺƔ|oƑƓĺƔő
 – No change
 – Pre- versus post-conflict:
 – 59.0 (95% CI 24.0 to 94.0)
 – Increase
 – During versus post-conflict:
 – 66.0 (95% CI 31.0 to 101.0)
 – Increase
-;l-|oѴo]b1-Ѵ1-m1;uv
Author, funding, ethics Study design and setting Study characteristics Outcome
-0-uƑƏƏƓ
• Funding: Not 
reported
• Ethics: Not 
reported
• Design: Ecological
• Conflict: Croatian War of 
Independence (1991 to 
1995)
• Jurisdiction: National
• Setting: Community
• Exposure: Uniform
• "|7;-uĹƐƖѶѵƴƐƖƖѶ
• Sample size: 580
• Age: 0–14 years
• %Male: Not reported
• Time between exposure and 
outcome: 7 years
• NOS Score: 5
 – Selection: 3
 – Comparability: 1
 – Outcome: 1
• Outcome: Haematological malignancies
• Measured: Cancer Registry of Croatia
• Epidemiological measure: Incidence
• Effect estimate and direction (recalculated): 
 – Pre-conflict: 249 cases in 5 years
 – During conflict: 216 cases in 5 years
 – Post-conflict: 115 cases in 5 years
• Difference:
 – Pre- versus during conflict:
 – ƴƒƒĺƏŐƖƔѷƴƕƔĺƒ|oƖĺƒő
 – No change
 – Pre- versus post-conflict:
 – ƴƐƒƓĺƏŐƖƔѷƴƐѵƖĺƕ|oƴƖѶĺƒő
 – Decrease
 – During versus post-conflict:
 – ƴƐƏƐĺƏŐƖƔѷƴƐƒѵĺƕ|oƴѵƔĺƒő
 – Decrease
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• Outcome: Hodgkin’s lymphoma
• Measured: Cancer Registry of Croatia
• Epidemiological measure: Incidence
• Effect estimate and direction (recalculated): 
 – Pre-conflict: 29 cases in 5 years
 – During conflict: 25 cases in 5 years
 – Post-conflict: 10 cases in 5 years
• Difference:
 – Pre- versus during conflict:
 – ƴƓĺƏŐƖƔѷƴƐѶĺƓ|oƐƏĺƓő
 – No change
 – Pre- versus post-conflict:
 – ƴƐƖĺƏŐƖƔѷƴƒƏĺѵ|oƴƐƔĺƏő
 – Decrease
 – During versus post-conflict:
 – ƴƐƔĺƏŐƖƔѷƴƑѵĺѵ|oƴƒĺƓő
 – Decrease
• Outcome: Non-Hodgkin’s lymphoma
• Measured: Cancer Registry of Croatia
• Epidemiological measure: Incidence
• Effect estimate and direction (recalculated): 
 – Pre-conflict: 54 cases in 5 years
 – During conflict: 44 cases in 5 years
 – Post-conflict: 18 cases in 5 years
• Difference:
 – Pre- versus during conflict:
 – ƴƐƏĺƏŐƖƔѷƴƑƖĺƓ|oƖĺƓő
 – No change
 – Pre- versus post-conflict:
 – ƴƒѵĺƏŐƖƔѷƴƔƐĺƓ|oƴƑƏĺѵő
 – Decrease
 – During versus post-conflict:
 – ƴƑѵĺƏŐƖƔѷƴƓƐĺƓ|oƴƐƏĺѵő
 – Decrease
• Outcome: Lymphatic leukaemia
• Measured: Cancer Registry of Croatia
• Epidemiological measure: Incidence
• Effect estimate and direction (recalculated): 
 – Pre-conflict: 129 cases in 5 years
 – During conflict: 132 cases in 5 years
 – Post-conflict: 69 cases in 5 years
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• Difference:
 – Pre- versus during conflict:
 – ƒĺƏŐƖƔѷƴƑѶĺƕ|oƒƓĺƕő
 – No change
 – Pre- versus post-conflict:
 – ƴѵƐĺƏŐƖƔѷƴѶѶĺƕ|oƴƒƒĺƒő
 – Decrease
 – During versus post-conflict:
 – ƴѵƓĺƏŐƖƔѷƴƖƐĺƕ|oƴƒѵĺƒő
 – Decrease
• Outcome: Myeloid leukaemia
• Measured: Cancer Registry of Croatia
• Epidemiological measure: Incidence
• Effect estimate and direction (recalculated): 
 – Pre-conflict: 37 cases in 5 years
 – During conflict: 15 cases in 5 years
 – Post-conflict: 19 cases in 5 years
• Difference:
 – Pre- versus during conflict:
 – ƴƑƑĺƏŐƖƔѷƴƒѵĺƐ|oƴƕĺƖő
 – Decrease
 – Pre- versus post-conflict:
 – ƴƐѶĺƏŐƖƔѷƴƑƖĺƓ|oƴѵĺѵő
 – Decrease
 – During versus post-conflict:
 – ƓĺƏŐƖƔѷƴƕĺƓ|oƐƔĺƓő
 – No change
-0-uƑƏƏƓ
• Funding: Not 
reported
• Ethics: Not 
reported
• Design: Ecological
• Conflict: Croatian War of 
Independence (1991 to 
1995)
• Jurisdiction: National
• Setting: Community
• Exposure: Chemical 
damage
• Study year: 1986–1998
• Sample size: 580
• Age: 0–14 years
• %Male: Not reported
• Time between exposure and 
outcome: 7 years
• NOS Score: 5
 – Selection: 3
 – Comparability: 1
 – Outcome: 1
• Outcome: Hodgkin’s lymphoma
• Measured: Cancer Registry of Croatia
• Epidemiological measure: Incidence
• Effect estimate and direction (recalculated): 
 – Pre-conflict: 3 cases in 5 years
 – During conflict: 3 cases in 5 years
 – Post-conflict: 0 cases in 5 years
• Difference:
 – Pre- versus during conflict:
 – ƏĺƏŐƖƔѷƴƓĺѶ|oƓĺѶő
 – No change
 – Pre- versus post-conflict:
 – ƴƒĺƏŐƖƔѷƴѵĺƓ|oƏĺƓő
 – No change
 – During versus post-conflict:
 – ƴƒĺƏŐƖƔѷƴѵĺƓ|oƏĺƓő
 – No change
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• Outcome: Non-Hodgkin’s lymphoma
• Measured: Cancer Registry of Croatia
• Epidemiological measure: Incidence
• Effect estimate and direction (recalculated): 
 – Pre-conflict: 1 case in 5 years
 – During conflict: 3 cases in 5 years
 – Post-conflict: 2 cases in 5 years
• Difference:
 – Pre- versus during conflict:
 – ƑĺƏŐƖƔѷƴƐĺƖ|oƔĺƖő
 – No change
 – Pre- versus post-conflict:
 – ŐƖƔѷƴƒĺƓ|oƔĺƓő
 – No change
 – During versus post-conflict:
 – ƴƐĺƏŐƖƔѷƴƔĺƓ|oƒĺƓő
 – No change
• Outcome: Lymphatic leukaemia
• Measured: Cancer Registry of Croatia
• Epidemiological measure: Incidence
• Effect estimate and direction (recalculated): 
 – Pre-conflict: 12 cases in 5 years
 – During conflict: 6 cases in 5 years
 – Post-conflict: 2 cases in 5 years
• Difference:
 – Pre- versus during conflict:
 – ƴѵĺƏŐƖƔѷƴƐƓĺƒ|oƑĺƒő
 – No change
 – Pre- versus post-conflict:
 – ƴƐƏĺƏŐƖƔѷƴƐƔĺƔ|oƓĺƔő
 – Decrease
 – During versus post-conflict:
 – ƴƓĺƏŐƖƔѷƴƖĺƔ|oƐĺƔő
 – No change
• Outcome: Myeloid leukaemia
• Measured: Cancer Registry of Croatia
• Epidemiological measure: Incidence
• Effect estimate and direction (recalculated): 
 – Pre-conflict: 3 cases in 5 years
 – During conflict: 1 case in 5 years
 – Post-conflict: 0 cases in 5 years
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• Difference:
 – Pre- versus during conflict:
 – ƴƑĺƏŐƖƔѷƴƔĺƖ|oƐĺƖő
 – No change
 – Pre- versus post-conflict:
 – ƴƒĺƏŐƖƔѷƴƔĺƏ|oƴƐĺƏő
 – No change
 – During versus post-conflict:
 – ƴƐĺƏŐƖƔѷƴƒĺƏ|oƐĺƏő
 – No change
-0-uƑƏƏƓ
• Funding: Not 
reported
• Ethics: Not 
reported
• Design: Ecological
• Conflict: Croatian War of 
Independence (1991 to 
1995)
• Jurisdiction: National
• Setting: Community
• Exposure: Chemical 
damage
• Study year: 1986–1998
• Sample size: 580
• Age: 0–14 years
• %Male: Not reported
• Time between exposure and 
outcome: 7 years
• NOS Score: 5
 – Selection: 3
 – Comparability: 1
 – Outcome: 1
• Outcome: Hodgkin’s lymphoma
• Measured: Cancer Registry of Croatia
• Epidemiological measure: Incidence
• Effect estimate and direction (recalculated): 
 – Pre-conflict: 3 cases in 5 years
 – During conflict: 3 cases in 5 years
 – Post-conflict: 0 cases in 5 years
• Difference:
 – Pre- versus during conflict:
 – ƏĺƏŐƖƔѷƴƓĺѶ|oƓĺѶő
 – No change
 – Pre- versus post-conflict:
 – ƴƒĺƏŐƖƔѷƴѵĺƓ|oƏĺƓő
 – No change
 – During versus post-conflict:
 – ƴƒĺƏŐƖƔѷƴѵĺƓ|oƏĺƓő
 – No change
• Outcome: Non-Hodgkin’s lymphoma
• Measured: Cancer Registry of Croatia
• Epidemiological measure: Incidence
• Effect estimate and direction (recalculated): 
 – Pre-conflict: 1 case in 5 years
 – During conflict: 3 cases in 5 years
 – Post-conflict: 2 cases in 5 years
• Difference:
 – Pre- versus during conflict:
 – ƑĺƏŐƖƔѷƴƐĺƖ|oƔĺƖő
 – No change
 – Pre- versus post-conflict:
 – ŐƖƔѷƴƒĺƓ|oƔĺƓő
 – No change
 – During versus post-conflict:
 – ƴƐĺƏŐƖƔѷƴƔĺƓ|oƒĺƓő
 – No change
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• Outcome: Lymphatic leukaemia
• Measured: Cancer Registry of Croatia
• Epidemiological measure: Incidence
• Effect estimate and direction (recalculated): 
 – Pre-conflict: 12 cases in 5 years
 – During conflict: 6 cases in 5 years
 – Post-conflict: 2 cases in 5 years
• Difference:
 – Pre- versus during conflict:
 – ƴѵĺƏŐƖƔѷƴƐƓĺƒ|oƑĺƒő
 – No change
 – Pre- versus post-conflict:
 – ƴƐƏĺƏŐƖƔѷƴƐƔĺƔ|oƓĺƔő
 – Decrease
 – During versus post-conflict:
 – ƴƓĺƏŐƖƔѷƴƖĺƔ|oƐĺƔő
 – No change
• Outcome: Myeloid leukaemia
• Measured: Cancer Registry of Croatia
• Epidemiological measure: Incidence
• Effect estimate and direction (recalculated): 
 – Pre-conflict: 3 cases in 5 years
 – During conflict: 1 case in 5 years
 – Post-conflict: 0 cases in 5 years
• Difference:
 – Pre- versus during conflict:
 – ƴƑĺƏŐƖƔѷƴƔĺƖ|oƐĺƖő
 – No change
 – Pre- versus post-conflict:
 – ƴƒĺƏŐƖƔѷƴƔĺƏ|oƴƐĺƏő
 – No change
 – During versus post-conflict:
 – ƴƐĺƏŐƖƔѷƴƒĺƏ|oƐĺƏő
 – No change
-0-uƑƏƏƓ
• Funding: Not 
reported
• Ethics: Not 
reported
• Design: Ecological
• Conflict: Croatian War of 
Independence (1991 to 
1995)
• Jurisdiction: National
• Setting: Community
• Exposure: Depleted 
uranium
• "|7;-uĹƐƖѶѵƴƐƖƖѶ
• Sample size: 580
• Age: 0–14 years
• %Male: Not reported
• Time between exposure and 
outcome: 7 years
• NOS Score: 5
 – Selection: 3
 – Comparability: 1
 – Outcome: 1
• Outcome: Hodgkin’s lymphoma
• Measured: Cancer Registry of Croatia
• Epidemiological measure: Incidence
• Effect estimate and direction (recalculated): 
 – Pre-conflict: 8 cases in 5 years
 – During conflict: 9 cases in 5 years
 – Post-conflict: 2 cases in 5 years
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• Difference:
 – Pre- versus during conflict:
 – ŐƖƔѷƴƕĺƐ|oƖĺƐő
 – No change
 – Pre- versus post-conflict:
 – ƴѵĺƏŐƖƔѷƴƐƑĺƔ|oƏĺƔő
 – No change
 – During versus post-conflict:
 – ƴƕĺƏŐƖƔѷƴƐƒĺƔ|oƴƏĺƔő
 – Decrease
• Outcome: Non-Hodgkin’s lymphoma
• Measured: Cancer Registry of Croatia
• Epidemiological measure: Incidence
• Effect estimate and direction (recalculated): 
 – Pre-conflict: 14 cases in 5 years
 – During conflict: 12 cases in 5 years
 – Post-conflict: 7 cases in 5 years
• Difference:
 – Pre- versus during conflict:
 – ƴƑĺƏŐƖƔѷƴƐƑĺƏ|oѶĺƏő
 – No change
 – Pre- versus post-conflict:
 – ƴƕĺƏŐƖƔѷƴƐƔĺƔ|oƐĺƔő
 – No change
 – During versus post-conflict:
 – ƴƔĺƏŐƖƔѷƴƐƒĺƔ|oƒĺƔő
 – No change
• Outcome: Lymphatic leukaemia
• Measured: Cancer Registry of Croatia
• Epidemiological measure: Incidence
• Effect estimate and direction (recalculated): 
 – Pre-conflict: 59 cases in 5 years
 – During conflict: 36 cases in 5 years
 – Post-conflict: 25 cases in 5 years
• Difference:
 – Pre- versus during conflict:
 – ƴƑƒĺƏŐƖƔѷƴƓƑĺƐ|oƴƒĺƖő
 – Decrease
 – Pre- versus post-conflict:
 – ƴƒƓĺƏŐƖƔѷƴƓƖĺƒ|oƴƐѶĺƕő
 – Decrease
 – During versus post-conflict:
 – ƴƐƐĺƏŐƖƔѷƴƑѵĺƒ|oƓĺƒő
 – No change
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• Outcome: Myeloid leukaemia
• Measured: Cancer Registry of Croatia
• Epidemiological measure: Incidence
• Effect estimate and direction (recalculated): 
 – Pre-conflict: 13 cases in 5 years
 – During conflict: 3 cases in 5 years
 – Post-conflict: 5 cases in 5 years
• Difference:
 – Pre- versus during conflict:
 – ƴƐƏĺƏŐƖƔѷƴƐƕĺѶ|oƴƑĺƑő
 – Decrease
 – Pre- versus post-conflict:
 – ƴѶĺƏŐƖƔѷƴƐƒĺƔ|oƴƑĺƔő
 – No change
 – During versus post-conflict:
 – ƑĺƏŐƖƔѷƴƒĺƔ|oƕĺƔő
 – No change
-0-uƑƏƏƓ
• Funding: Not 
reported
• Ethics: Not 
reported
• Design: Ecological
• Conflict: Croatian War of 
Independence (1991 to 
1995)
• Jurisdiction: National
• Setting: Community
• Exposure: Population 
mixing
• Study year: 1986–1998
• Sample size: 580
• Age: 0–14 years
• %Male: Not reported
• Time between exposure and 
outcome: 7 years
• NOS Score: 5
 – Selection: 3
 – Comparability: 1
 – Outcome: 1
• Outcome: Hodgkin’s lymphoma
• Measured: Cancer Registry of Croatia
• Epidemiological measure: Incidence
• Effect estimate and direction (recalculated): 
 – Pre-conflict: 15 cases in 5 years
 – During conflict: 4 cases in 5 years
 – Post-conflict: 1 case in 5 years
• Difference:
 – Pre- versus during conflict:
 – ƴƐƐĺƏŐƖƔѷƴƐƖĺƔ|oƴƑĺƔő
 – Decrease
 – Pre- versus post-conflict:
 – ƴƐƓĺƏŐƖƔѷƴƐѶĺƓ|oƴƖĺѵő
 – Decrease
 – During versus post-conflict:
 – ƴƒĺƏŐƖƔѷƴƕĺƓ|oƐĺƓő
 – No change
• Outcome: Non-Hodgkin’s lymphoma
• Measured: Cancer Registry of Croatia
• Epidemiological measure: Incidence
• Effect estimate and direction (recalculated): 
 – Pre-conflict: 22 cases in 5 years
 – During conflict: 16 cases in 5 years
 – Post-conflict: 8 cases in 5 years
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• Difference:
 – Pre- versus during conflict:
 – ƴѵĺƏŐƖƔѷƴƐѶĺƐ|oѵĺƐő
 – No change
 – Pre- versus post-conflict:
 – ƴƐƓĺƏŐƖƔѷƴƑƒĺѵ|oƴƓĺƓő
 – Decrease
 – During versus post-conflict:
 – ƴѶĺƏŐƖƔѷƴƐƕĺѵ|oƐĺѵő
 – No change
• Outcome: Lymphatic leukaemia
• Measured: Cancer Registry of Croatia
• Epidemiological measure: Incidence
• Effect estimate and direction (recalculated): 
 – Pre-conflict: 41 cases in 5 years
 – During conflict: 59 cases in 5 years
 – Post-conflict: 26 cases in 5 years
• Difference:
 – Pre- versus during conflict:
 – ƐѶĺƏŐƖƔѷƴƐĺѵ|oƒƕĺѵő
 – No change
 – Pre- versus post-conflict:
 – ƴƐƔĺƏŐƖƔѷƴƒƒĺƐ|oƒĺƐő
 – No change
 – During versus post-conflict:
 – ƴƒƒĺƏŐƖƔѷƴƔƐĺƐ|oƴƐƓĺƖő
 – Decrease
• Outcome: Myeloid leukaemia
• Measured: Cancer Registry of Croatia
• Epidemiological measure: Incidence
• Effect estimate and direction (recalculated): 
 – Pre-conflict: 12 cases in 5 years
 – During conflict: 5 cases in 5 years
 – Post-conflict: 7 cases in 5 years
• Difference:
 – Pre- versus during conflict:
 – ƴƕĺƏŐƖƔѷƴƐƔĺƐ|oƐĺƐő
 – No change
 – Pre- versus post-conflict:
 – ƴƔĺƏŐƖƔѷƴƐƐĺѶ|oƐĺѶő
 – No change
 – During versus post-conflict:
 – ƑĺƏŐƖƔѷƴƓĺѶ|oѶĺѶő
 – No change
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Lung cancer
Author, funding, ethics Study design and setting Study characteristics Outcome
	lb|uob1ƑƏƏѵ
• Funding: Yes
• Ethics: Not 
reported
• Design: Ecological
• Conflict: Croatian War of 
Independence (1991 to 
1995)
• Jurisdiction: City
• Setting: Hospital
• Exposure: Uniform
• Study year: 1990–1993
• Sample size: 121
• Age: Not reported
• % Male: Not reported
• Time between exposure and 
outcome: 3 years
• NOS Score: 4
 – Selection: 3
 – Comparability: 0
 – Outcome: 1
• Outcome: Malignant lung cancer
• Measured: Pathohistological confirmation
• Epidemiological measure: Incidence
• Effect estimate and direction (recalculated): 
 – Pre-conflict: 63 cases in 2 years
 – During conflict: 58 cases in 2 years
 – 	b==;u;m1;ĹƴƔĺƏŐƖƔѷƴƑѵĺѵ|oƐѵĺѵő
 – No change
orbѴƑƏƏƖ
• Funding: Yes
• Ethics: Yes
• Design: Cohort
• Conflict: Siege of Lenin-
grad (1941–1944)
• Jurisdiction: City
• Setting: Community
• Exposure: Time of birth
• Study year: 2005
• Sample size: 4,172
• Age: 49 years
• % Male: 78
• Time between exposure and 
outcome: 64 years
• NOS Score: 7
 – Selection: 3
 – Comparability: 2
 – Outcome: 2
• Outcome: Respiratory cancer mortality
• Measured: Death certificates coded by physicians (ICD-
8)
• Epidemiological measure: Adjusted hazard ratios
• Effect estimate and direction (as reported):
 – 1.29 (95% CI 0.98 to 1.70)
 – No change
(-];uoƑƏƐƒ
• Funding: Yes
• Ethics: Yes
• Design: Cohort
• Conflict: Siege of Lenin-
grad (1941–1944)
• Jurisdiction: City
• Setting: Community
• Exposure: Time of birth
• Study year: 1975–1977 (men); 
1980–1982 (women)
• Sample size: 5,327
• Age: Not reported
• % Male: 73
• Time between exposure and 
outcome: 41 years
• NOS Score: 3
 – Selection: 2
 – Comparability: 0
 – Outcome: 1
• Outcome: Respiratory cancer mortality
• Measured: Death certificates coded by physicians  
(ICD-8)
• Epidemiological measure: Relative risk
• Effect estimate and direction (as reported): 
 – 1.89 (95% CI 0.83 to 4.31)
 – No change
Oropharyngeal cancer
Author, funding, ethics Study design and setting Study characteristics Outcome
ub--u7-m-ƑƏƐƐ
• Funding: Yes
• Ethics: Not 
reported
• Design: Ecological
• Conflict: Sri Lankan Civil 
War (1983–2009)
• Jurisdiction: National
• Setting: Hospital
• Exposure: Uniform
• Study year: 1985–2005
• Sample size: 6,391
• Age: All ages
• %Male: 75
• Time between exposure and 
outcome: 20 years
• NOS Score: 5
 – Selection: 3
 – Comparability: 1
 – Outcome: 1
• Outcome: Oropharyngeal cancers
• Measured: Hospital registries
• Epidemiological measure: Beta coefficient (age stan-
dardised)
• Effect estimate and direction (as reported): 
 – - 0.0092, p = 0.043
 – - Increase
• Outcome: Lip and oral cavity cancers
• Measured: Hospital registries
• Epidemiological measure: Beta coefficient (age stan-
dardised)
• Effect estimate and direction (as reported):
 – ƴƏĺƐƕķp = 0.0028
 – Decrease
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Ovarian cancer
Author, funding, ethics Study design and setting Study characteristics Outcome
	lb|uob1ƑƏƏѵ
• Funding: Yes
• Ethics: Not 
reported
• Design: Ecological
• Conflict: Croatian War of 
Independence (1991 to 
1995)
• Jurisdiction: City
• Setting: Hospital
• Exposure: Uniform
• Study year: 1990–1993
• Sample size: 62
• Age: Not reported
• % Male: Not reported
• Time between exposure and 
outcome: 3 years
• NOS Score: 4
 – Selection: 3
 – Comparability: 0
 – Outcome: 1
• Outcome: Malignant ovarian cancer
• Measured: Pathohistological confirmation
• Epidemiological measure: Incidence
• Effect estimate and direction (recalculated):
 – Pre-conflict: 16 cases in 2 years
 – During conflict: 46 cases in 2 years
 – Difference: 30.0 (95% CI 14.6 to 45.4)
 – Increase
bѴofhob1ƑƏƏƔ
• Funding: Not 
reported
• Ethics: Not 
reported
• Design: Ecological
• Conflict: Croatian War of 
Independence (1991 to 
1995)
• Jurisdiction: City
• Setting: Hospital
• Exposure: Uniform
• Study year: 1984–2002
• Sample size: 262
• Age: Not reported
• % Male: Not reported
• Time between exposure and 
outcome: 10 years
• NOS Score: 4
 – Selection: 3
 – Comparability: 0
 – Outcome: 1
• Outcome: Ovarian cancer, unspecified
• Measured: Histological confirmation
• Epidemiological measure: Incidence
• Effect estimate and direction (recalculated):
 – Pre-conflict: 90 cases in 6 years
 – During conflict: 85 cases in 6 years
 – Post-conflict: 144 cases in 6 years
• Difference:
 – Pre- versus during conflict:
 – ƴƔĺƏŐƖƔѷƴƒƏĺƖ|oƑƏĺƖő
 – No change
 – Pre- versus post-conflict:
 – 54.0 (95% CI 24.3 to 83.7)
 – Increase
 – During versus post-conflict:
 – 59.0 (95% CI 29.3 to 88.7)
 – Increase
Pancreatic  cancer
Author, funding, ethics Study design and setting Study characteristics Outcome
	lb|uob1ƑƏƏѵ
• Funding: Yes
• Ethics: Not 
reported
• Design: Ecological
• Conflict: Croatian War of 
Independence (1991 to 
1995)
• Jurisdiction: City
• Setting: Hospital
• Exposure: Uniform
• Study year: 1990–1993
• Sample size: 8
• Age: Not reported
• % Male: Not reported
• Time between exposure and 
outcome: 3 years
• NOS Score: 4
 – Selection: 3
 – Comparability: 0
 – Outcome: 1
• Outcome: Malignant pancreatic cancer
• Measured: Pathohistological confirmation
• Epidemiological measure: Incidence
• Effect estimate and direction (recalculated): 
 – Pre-conflict: 5 cases in 2 years
 – During conflict: 3 cases in 2 years
 – 	b==;u;m1;ĹƴƑĺƏŐƖƔѷƴƕĺƔ|oƒĺƔő
 – No change
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Prostate cancer
Author, funding, ethics Study design and setting Study characteristics Outcome
orbѴƑƏƏƖ
• Funding: Yes
• Ethics: Yes
• Design: Cohort
• Conflict: Siege of Lenin-
grad (1941–1944)
• Jurisdiction: City
• Setting: Community
• Exposure: Time of birth
• Study year: 2005
• Sample size: 4,172
• Age: 49 years
• % Male: 78
• Time between exposure and 
outcome: 64 years
• NOS Score: 7
 – Selection: 3
 – Comparability: 2
 – Outcome: 2
• Outcome: Prostate cancer mortality
• Measured: Death certificates coded by physicians (ICD-
8)
• Epidemiological measure: Adjusted hazard ratios
• Effect estimate and direction (as reported): 
 – 1.43 (95% CI 0.70 to 2.92)
 – No change
Stomach cancer
Author, funding, ethics Study design and setting Study characteristics Outcome
	lb|uob1ƑƏƏѵ
• Funding: Yes
• Ethics: Not 
reported
• Design: Ecological
• Conflict: Croatian War of 
Independence (1991 to 
1995)
• Jurisdiction: City
• Setting: Hospital
• Exposure: Uniform
• Study year: 1990–1993
• Sample size: 76
• Age: Not reported
• % Male: Not reported
• Time between exposure and 
outcome: 3 years
• NOS Score: 4
 – Selection: 3
 – Comparability: 0
 – Outcome: 1
• Outcome: Malignant stomach cancer
• Measured: Pathohistological confirmation
• Epidemiological measure: Incidence
• Effect estimate and direction (recalculated):
 – Pre-conflict: 17 cases in 2 years
 – During conflict: 59 cases in 2 years
 – Difference: 42.0 (95% CI 24.9 to 59.1)
 – Increase
orbѴƑƏƏƖ
• Funding: Yes
• Ethics: Yes
• Design: Cohort
• Conflict: Siege of Lenin-
grad (1941–1944)
• Jurisdiction: City
• Setting: Community
• Exposure: Time of birth
• Study year: 2005
• Sample size: 4,172
• Age: 49 years
• % Male: 78
• Time between exposure and 
outcome: 64 years
• NOS Score: 7
 – Selection: 3
 – Comparability: 2
 – Outcome: 2
• Outcome: Stomach cancer mortality
• Measured: Death certificates coded by physicians  
(ICD-8)
• Epidemiological measure: Adjusted hazard ratios
• Effect estimate and direction (as reported): 
 – 0.95 (95% CI 0.65–1.37)
 – No change
Testicular cancer
Author, funding, ethics Study design and setting Study characteristics Outcome
	lb|uob1ƑƏƏѵ
• Funding: Yes
• Ethics: Not 
reported
• Design: Ecological
• Conflict: Croatian War of 
Independence (1991 to 
1995)
• Jurisdiction: City
• Setting: Hospital
• Exposure: Uniform
• Study year: 1990–1993
• Sample size: 26
• Age: Not reported
• % Male: Not reported
• Time between exposure and 
outcome: 3 years
• NOS Score: 4
 – Selection: 3
 – Comparability: 0
 – Outcome: 1
• Outcome: Malignant cancer of the testis
• Measured: Pathohistological confirmation
• Epidemiological measure: Incidence
• Effect estimate and direction (recalculated): 
 – Pre-conflict: 6 cases in 2 years
 – During conflict: 20 cases in 2 years
 – Difference: 14.0 (95% CI 4.0 to 24.0)
 – Increase
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Cancer, unspecified site
Author, funding, ethics Study design and setting Study characteristics Outcome
Adib 1998 
• Funding: Yes
• Ethics: Not 
reported
• Design: Ecological
• Conflict: Lebanese Civil 
War (1975–1991)
• Jurisdiction: City
• Setting: Hospital
• Exposure: Uniform
• Study year: 1983–1994
• Sample size: 9,364
• Age: 49–52 years
• % Male: 50
• Time between exposure and 
outcome: 11 years
• NOS Score: 4
 – Selection: 3
 – Comparability: 0
 – Outcome: 1
• Outcome: Unspecified
• Measured: Pathology and cytology
• Epidemiological measure: Incidence
• Effect estimate and direction (recalculated): 
 – During conflict: Mean 785.8 cases/year
 – Post-conflict: Mean 802.3 cases/year
 – 	b==;u;m1;ĹƐѵĺƔŐƖƔѷƴѵƐĺѵ|oƖƓĺѵő
 – No change
ѴŊ-v_blbƑƏƐƒ
• Funding: None
• Ethics: Not 
reported
• Design: Ecological
• Conflict: Unspecified 
conflicts in Iraq
• Jurisdiction: Subnational
• Setting: Hospital
• Exposure: Uniform
• Study year: 1980–2010
• Sample size: Not reported
• Age: Not reported
• % Male: Not reported
• Time between exposure and 
outcome: 30 years
• NOS Score: 4
 – Selection: 3
 – Comparability: 0
 – Outcome: 1
• Outcome: Unspecified
• Measured: Hospital records
• Epidemiological measure: Incidence rate
• Effect estimate and direction (as reported): 
 – Pre-conflict (1980 to 1989): 7.8 (95% CI 6.9 to 
8.7)
 – During conflict (1990 to 1999): 10.5 (95% CI 10.2 
to 10.8)
 – During conflict (2000–2010): 10.2 (95% CI 9.7 to 
10.7)
 – Increase
	lb|uob1ƑƏƏѵ
• Funding: Yes
• Ethics: Not 
reported
• Design: Ecological
• Conflict: Croatian War of 
Independence (1991 to 
1995)
• Jurisdiction: City
• Setting: Hospital
• Exposure: Uniform
• Study year: 1990–1993
• Sample size: 509
• Age: Not reported
• % Male: Not reported
• Time between exposure and 
outcome: 3 years
• NOS Score: 4
 – Selection: 3
 – Comparability: 0
 – Outcome: 1
• Outcome: Malignant tumours, unspecified
• Measured: Pathohistological confirmation
• Epidemiological measure: Incidence
• Effect estimate and direction (recalculated): 
 – Pre-conflict: 254 cases in 2 years
 – During conflict: 255 cases in 2 years
 – 	b==;u;m1;ĹƐĺƏŐƖƔѷƴŋƴƓƒĺƑ|oƓƔĺƑő
 – No change
	uѴf;b1ƑƏƏƔ
• Funding: Not 
reported
• Ethics: Not 
reported
• Design: Ecological
• Conflict: Bosnian War 
(1992–1995)
• Jurisdiction: City
• Setting: Hospital
• Exposure: Uniform
• Study year: 1992–2000
• Sample size: 855
• Age: Not reported
• % Male: 0
• Time between exposure and 
outcome: 9 years
• NOS Score: 4
 – Selection: 3
 – Comparability: 0
 – Outcome: 1
• Outcome: Female genital cancers
• Measured: Hospital records
• Epidemiological measure: Incidence
• Effect estimate and direction (as reported):
 – Pre- versus during conflict: No change
 – Pre- versus post-conflict: Increase
Re
vi
ew
ecancer 2020, 14:1039; www.ecancer.org; DOI: https://doi.org/10.3332/ecancer.2020.1039 40
Cancer, unspecified site
Author, funding, ethics Study design and setting Study characteristics Outcome
-]orb-mƑƏƐƒ
• Funding: None
• Ethics: Yes
• Design: Cross-sectional
• Conflict: Iraq War 
(2003–2011)
• Jurisdiction: National
• Setting: Community
• Exposure: Uniform
• Study year: 2001–2011
• Sample size: 35,835
• Age: Not reported
• % Male: Not reported
• Time between exposure and 
outcome: 9 years
• NOS Score: 5
 – Selection: 4
 – Comparability: 0
 – Outcome: 1
• Outcome: Cancer mortality
• Measured: Self-reported
• Epidemiological measure: Incidence
• Effect estimate and direction (recalculated): 
 – Pre-conflict: Mean 9.9 cases/year
 – During conflict: Mean 14.8 cases/year
 – Difference: 4.9 (95% CI 0.4 to 9.4)
 – Increase
orbѴƑƏƏƖ
• Funding: Yes
• Ethics: Yes
• Design: Cohort
• Conflict: Siege of Lenin-
grad (1941–1944)
• Jurisdiction: City
• Setting: Community
• Exposure: Time of birth
• Study year: 2005
• Sample size: 4,172
• Age: 49 years
• % Male: 78
• Time between exposure and 
outcome: 64 years
• NOS Score: 7
 – Selection: 3
 – Comparability: 2
 – Outcome: 2
• Outcome: All cancer mortality
• Measured: Death certificates coded by physicians  
(ICD-8)
• Epidemiological measure: Adjusted hazard ratios
• Effect estimate and direction (as reported): 
 – 1.12 (95% CI 0.95 to 1.31)
 – No change
(-];uoƑƏƐƒ
• Funding: Yes
• Ethics: Yes
• Design: Cohort
• Conflict: Siege of Lenin-
grad (1941–1944)
• Jurisdiction: City
• Setting: Community
• Exposure: Time of birth
• Study year: 1975–1977 (men); 
1980–1982 (women)
• Sample size: 5,327
• Age: Not reported
• % Male: 73
• Time between exposure and 
outcome: 41 years
• NOS Score: 3
 – Selection: 2
 – Comparability: 0
 – Outcome: 1
• Outcome: All cancer mortality
• Measured: Death certificates coded by physicians  
(ICD-8)
• Epidemiological measure: Relative risk
• Effect estimate and direction (as reported): 
 – 1.11 (95% CI 0.97 to 1.27)
 – No change
(Ѵ-fbm-1ƑƏƏƏ
• Funding: Yes
• Ethics: Yes
• Design: Ecological
• Conflict: Non-specific 
conflicts following the 
breakup up Yugoslavia
• Jurisdiction: Subnational
• Setting: Community
• Exposure: Uniform
• Study year: 1973–1994
• Sample size: Not reported
• Age: All ages
• %Male: Not reported
• Time between exposure and 
outcome: 21 years
• NOS Score: 4
 – Selection: 3
 – Comparability: 0
 – Outcome: 1
• Outcome: Unspecified cancer mortality
• Measured: Federal Institute of Statistics, Serbia
• Epidemiological measure: Beta coefficient
• Effect estimate and direction (as reported): 
 – y = 428.01 + 21.427x ƴ ƐѵƕĺѵƐ Ő)-uőķ 
p = 0.031
 – Decrease
